Evaluation of the Efficacy of BCG in Protecting Against Contact Challenge With Bovine Tuberculosis in Holstein-Friesian and Zebu Crossbred Calves in Ethiopia.
Ethiopia
bovine tuberculosis
crossbred cattle
efficacy of BCG
natural transmission
Journal
Frontiers in veterinary science
ISSN: 2297-1769
Titre abrégé: Front Vet Sci
Pays: Switzerland
ID NLM: 101666658
Informations de publication
Date de publication:
2021
2021
Historique:
received:
29
04
2021
accepted:
11
06
2021
entrez:
9
8
2021
pubmed:
10
8
2021
medline:
10
8
2021
Statut:
epublish
Résumé
Bovine tuberculosis (bTB) is prevalent in intensive dairy farms in Ethiopia. Vaccination could be an alternative control approach given the socio-economic challenges of a test-and-slaughter control strategy. The efficacy of the BCG was evaluated on 40 Holstein-Friesian (HF) and zebu crossbred calves recruited from single intradermal cervical comparative tuberculin (SICCT) test negative herds and randomly allocated into two groups. Twenty-two calves were vaccinated within 2 weeks of age, and 18 were kept as a control. Six weeks post-vaccination, the two groups were exposed and kept mixed with known SICCT test positive cows for 1 year. Immune responses were monitored by interferon gamma (IFN-γ) release assay (IGRA), SICCT test, and antibody assay. Vaccinated calves developed strong responses to the SICCT test at the sixth week post-vaccination, but did not respond to ESAT-6/CFP-10 peptide antigen-based IGRA. During the exposure, IFN-γ response to the specific peptide cocktail [
Identifiants
pubmed: 34368285
doi: 10.3389/fvets.2021.702402
pmc: PMC8339472
doi:
Types de publication
Journal Article
Langues
eng
Pagination
702402Subventions
Organisme : FIC NIH HHS
ID : D43 TW009127
Pays : United States
Informations de copyright
Copyright © 2021 Bayissa, Sirak, Worku, Zewude, Zeleke, Chanyalew, Gumi, Berg, Conlan, Hewinson, The ETHICOBOTS Consortium, Wood, Vordermeier and Ameni.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Transbound Emerg Dis. 2018 Feb;65(1):96-104
pubmed: 28168855
Transbound Emerg Dis. 2010 Aug 1;57(4):205-20
pubmed: 20561288
Scand J Immunol. 1996 May;43(5):490-9
pubmed: 8633206
Trop Anim Health Prod. 2010 Jun;42(5):915-20
pubmed: 19957029
Clin Diagn Lab Immunol. 1999 Sep;6(5):675-82
pubmed: 10473516
J Clin Microbiol. 2010 Sep;48(9):3176-81
pubmed: 20592155
Clin Vaccine Immunol. 2012 Aug;19(8):1254-60
pubmed: 22718125
Res Vet Sci. 2006 Oct;81(2):190-210
pubmed: 16513150
J Immunoassay Immunochem. 2002;23(2):245-53
pubmed: 12033646
BMC Vet Res. 2017 Aug 17;13(1):252
pubmed: 28818102
Vet Immunol Immunopathol. 2007 Jul 15;118(1-2):50-8
pubmed: 17524495
Front Vet Sci. 2018 Oct 26;5:259
pubmed: 30417002
Res Vet Sci. 2014 Oct;97 Suppl:S20-9
pubmed: 24731532
Tuberculosis (Edinb). 2001;81(1-2):23-41
pubmed: 11463222
Immunology. 2005 Jan;114(1):101-11
pubmed: 15606800
Korean J Food Sci Anim Resour. 2014;34(1):7-13
pubmed: 26760739
Transbound Emerg Dis. 2021 Apr 19;:
pubmed: 33872473
Tuberculosis (Edinb). 2016 Dec;101:102-113
pubmed: 27865379
Prev Vet Med. 2017 Nov 1;147:149-157
pubmed: 29254713
Scand J Immunol. 1996 Apr;43(4):374-80
pubmed: 8668915
J Comp Pathol. 2005 Nov;133(4):223-34
pubmed: 16154140
Front Immunol. 2019 Jun 11;10:1317
pubmed: 31244856
J Clin Microbiol. 1997 Apr;35(4):907-14
pubmed: 9157152
Transbound Emerg Dis. 2009 Aug;56(6-7):269-74
pubmed: 19575746
Sci Rep. 2020 Nov 23;10(1):20369
pubmed: 33230112
Infect Immun. 2004 May;72(5):2462-7
pubmed: 15102752
Front Vet Sci. 2021 Feb 18;8:637580
pubmed: 33681334
Prev Vet Med. 2012 Jun 1;105(1-2):149-54
pubmed: 22391021
Transbound Emerg Dis. 2013 Dec;60(6):525-37
pubmed: 22909117
PLoS One. 2017 Nov 20;12(11):e0188448
pubmed: 29155877
Infect Immun. 2002 Jun;70(6):3026-32
pubmed: 12010994
Rev Sci Tech. 2001 Apr;20(1):112-32
pubmed: 11288508
J Immunoassay Immunochem. 2010;31(2):160-8
pubmed: 20391027
Bull World Health Organ. 1985;63(6):1055-68
pubmed: 3879673
Transbound Emerg Dis. 2013 Nov;60 Suppl 1:136-46
pubmed: 24171859
Prev Vet Med. 2009 Jun 1;89(3-4):205-11
pubmed: 19339066
Annu Rev Anim Biosci. 2016;4:87-109
pubmed: 26884103
Infect Immun. 2003 Nov;71(11):6411-9
pubmed: 14573662
PLoS One. 2012;7(12):e52851
pubmed: 23285202
Lancet Microbe. 2020 Jun;1(2):e66-e73
pubmed: 32642742
Vaccine. 2012 Mar 30;30(16):2611-22
pubmed: 22342705
Braz J Biol. 2015 Nov;75(4):830-7
pubmed: 26675901
Vaccine. 2002 Jan 15;20(7-8):1126-33
pubmed: 11803073
Prev Vet Med. 2019 Jul 1;168:81-89
pubmed: 31097127
Tuberculosis (Edinb). 2020 May;122:101923
pubmed: 32275234
Infect Immun. 2007 Mar;75(3):1373-81
pubmed: 17194810
Clin Vaccine Immunol. 2010 Oct;17(10):1533-8
pubmed: 20719984
Vet J. 2011 Jun;188(3):359-61
pubmed: 20965132
Trop Anim Health Prod. 2012 Oct;44(7):1445-50
pubmed: 22286399
Comp Immunol Microbiol Infect Dis. 2012 May;35(3):227-32
pubmed: 22304898
Clin Vaccine Immunol. 2007 Oct;14(10):1356-61
pubmed: 17761523
Infect Immun. 2002 Feb;70(2):672-8
pubmed: 11796598
Vet Microbiol. 2017 Sep;208:181-189
pubmed: 28888636
Sci Rep. 2016 Mar 07;6:22763
pubmed: 26949166
Res Vet Sci. 2010 Feb;88(1):44-9
pubmed: 19564029